About Marval Biosciences
Marval Biosciences Inc., is an early stage company, developing the next generation of contrast agents for use in X-ray and Computed Tomography (CT) Imaging. Marvalís lead candidate, NCTX, targets cardiovascular imaging. NCTX is currently in the pre-IND developmental phase and therefore not FDA approved.
Video of NCTX Technology
Simultaneous imaging of the heart chambers and coronary arteries using NCTX in a sheep model. NCTX enables uniform and stable opacification of all vascular structures.
Imaging of lung vasculature. These images can be acquired simultaneously with cardiac imaging using a single dose of NCTX.